CA2403566A1 - Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia - Google Patents
Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia Download PDFInfo
- Publication number
- CA2403566A1 CA2403566A1 CA002403566A CA2403566A CA2403566A1 CA 2403566 A1 CA2403566 A1 CA 2403566A1 CA 002403566 A CA002403566 A CA 002403566A CA 2403566 A CA2403566 A CA 2403566A CA 2403566 A1 CA2403566 A1 CA 2403566A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- hode
- group
- disease
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HNICUWMFWZBIFP-IRQZEAMPSA-N 13(S)-HODE Chemical compound CCCCC[C@H](O)\C=C\C=C/CCCCCCCC(O)=O HNICUWMFWZBIFP-IRQZEAMPSA-N 0.000 title claims 2
- 206010020718 hyperplasia Diseases 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 230000002792 vascular Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 claims abstract 2
- 230000005764 inhibitory process Effects 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 238000000034 method Methods 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 10
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 8
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 8
- 241000251468 Actinopterygii Species 0.000 claims 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003921 oil Substances 0.000 claims 4
- 235000019198 oils Nutrition 0.000 claims 4
- 239000006014 omega-3 oil Substances 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 3
- 150000002148 esters Chemical group 0.000 claims 3
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 2
- 240000004355 Borago officinalis Species 0.000 claims 2
- 235000007689 Borago officinalis Nutrition 0.000 claims 2
- 244000020518 Carthamus tinctorius Species 0.000 claims 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims 2
- 244000020551 Helianthus annuus Species 0.000 claims 2
- 235000003222 Helianthus annuus Nutrition 0.000 claims 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims 2
- 241000219925 Oenothera Species 0.000 claims 2
- 235000004496 Oenothera biennis Nutrition 0.000 claims 2
- 240000007817 Olea europaea Species 0.000 claims 2
- 240000008042 Zea mays Species 0.000 claims 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 239000000561 aggregant Substances 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- 235000010323 ascorbic acid Nutrition 0.000 claims 2
- 229960005070 ascorbic acid Drugs 0.000 claims 2
- 239000011668 ascorbic acid Substances 0.000 claims 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000003086 colorant Substances 0.000 claims 2
- 235000005822 corn Nutrition 0.000 claims 2
- 235000012343 cottonseed oil Nutrition 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 239000008298 dragée Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 235000019688 fish Nutrition 0.000 claims 2
- 235000003599 food sweetener Nutrition 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- 229940087559 grape seed Drugs 0.000 claims 2
- 229940067606 lecithin Drugs 0.000 claims 2
- 239000000787 lecithin Substances 0.000 claims 2
- 235000010445 lecithin Nutrition 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 2
- 230000003204 osmotic effect Effects 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 239000003765 sweetening agent Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 229930003799 tocopherol Natural products 0.000 claims 2
- 239000011732 tocopherol Substances 0.000 claims 2
- 235000019149 tocopherols Nutrition 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 102000043136 MAP kinase family Human genes 0.000 claims 1
- 108091054455 MAP kinase family Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 102000003923 Protein Kinase C Human genes 0.000 claims 1
- 108090000315 Protein Kinase C Proteins 0.000 claims 1
- 208000026723 Urinary tract disease Diseases 0.000 claims 1
- 208000012931 Urologic disease Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- -1 auxiliary Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000008753 endothelial function Effects 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 210000004994 reproductive system Anatomy 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
- HNICUWMFWZBIFP-BSZOFBHHSA-N 13-HODE Chemical compound CCCCCC(O)\C=C\C=C/CCCCCCCC(O)=O HNICUWMFWZBIFP-BSZOFBHHSA-N 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000033228 biological regulation Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 235000005911 diet Nutrition 0.000 abstract 1
- 230000000378 dietary effect Effects 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 210000003989 endothelium vascular Anatomy 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Immunology (AREA)
Abstract
This invention relates to the regulation of vascular endothelium biocompatibility and to the inhibition of vessel wall cell and other types of cell hyperplasia following vessel wall dysfunction and/or injury. More particularly, the invention relates to the dietetic and pharmaceutical preparations of 13-hydroxyoctadeca-9Z, 11E-dienoic acid (13-HODE) and its use in reducing or inhibiting vessel wall hyperplasia and restoring vessel wall biocompatibility.
Claims (32)
1. A method of reducing or inhibiting cell hyperlasia and restoring vessel wall biocompatibility in a mammal or human in need of such treatment, comprising administering orally an amount of 13-hydroxyoctadeca-9Z, 11 E-dienoic acid (13-HODE) effective to reduce or inhibit vessel wall thrombogenicity.
2. The method of claim 1, wherein 13-HODE is administered as a pharmaceutical composition comprising 13-HODE and a pharmaceutically acceptable carrier, auxiliary, or excipient.
3. The method of claim 2, wherein the carrier is a mono-, di- or triglyceride oil.
4. The method of claim 2, wherein the carrier is selected from the group consisting of corn, sunflower, safflower, cottonseed, grape seed, olive, evening primrose, borage, fish body and fish liver oils.
5. The method of claim 2, wherein the carrier is an ester of a fatty acid containing 16-26 carbon atoms and one or more double bonds.
6. The method of claim 2, wherein the ester is selected from the group consisting of ethyl-eicosapentaenoic (ethyl-EPA), oleic, linoleic, alpha-linoleic, stearidonic, gamma-linolenic, dihomogammalinolenic, arachidonic, docosapentaenoic and docosahexaenoic (ethyl-DHA).
7. The method of claim 2, wherein the composition further comprises a fat-soluble antioxidant selected from the group consisting of ascorbyl palmitate, tocopherols, and ascorbic acid in the presence of lecithin.
8. The method of claim 2, wherein the composition further comprises an additive selected from the group consisting of aggregants, disaggregants, osmotic pressure regulating salts, buffers, sweeteners, and coloring agents.
9. The method of claim 2, wherein the composition is administered as a formulation selected from the group consisting of tablets, dragees, capsules, granules, solution, suspensions, and lyophilized compositions.
10. A method of correcting the inhibition of endogenous 13-HODE synthesis by omega-3 fatty acids by incorporating 13-HODE into formulations of omega-3 fatty acids.
11. The method of claim 1, wherein 13-HODE is administered as a pharmaceutical composition comprising 13-HODE and omega-3 fatty acids.
12. The method of claim 10 or 11, wherein the omega-3 fatty acid is selected from the group consisting of EPA, DHA, a derivative of EPA and a derivative of DHA.
13. The method of claim 10 or 11, wherein the omega-3 fatty acid is ethyl-EPA
or ethyl-DHA.
or ethyl-DHA.
14. A pharmaceutical composition for oral administration of 13-hydroxyoctadeca-9Z, 11 E-dienoic acid (13-HODE) in its free form.
15. A pharmaceutical composition of 13-hydroxyoctadeca-9Z, 11 E-dienoic acid (13-HODE) for oral administration, comprising, 13 HODE and a pharmaceutically acceptable carrier.
16. The pharmaceutical composition of claim 14 or 15 wherein the daily dose of 13-HODE is equal to or less than 100 mg.
17. The pharmaceutical composition of claim 15, wherein the carrier is a mono-, di- or triglyceride oil.
18. The pharmaceutical composition of claim 15, wherein the carrier is selected from the group consisting of corn, sunflower, safflower, cottonseed, grape seed, olive, evening primrose, borage, fish body, and fish liver oils.
19. The pharmaceutical composition of claim 15, wherein the carrier is an ester of a fatty acid containing 16-26 carbon atoms and one or more double bonds.
20. The pharmaceutical composition of claim 15, wherein the carrier is selected from the group consisting of ethyl-eicosapentaenoic (ethyl-EPA), oleic, linoleic, alpha-linolenic, stearidonic, gamma-linolenic, dihomogammalinolenic, arachidonic, docosapentaenoic and docosahexaenoic (ethyl-DHA).
21. The pharmaceutical composition of claim 14 or 15, wherein the composition is administered in the form selected from the group consisting of tablets, dragees, capsules, granules, solutions, suspensions and lyophilized compositions.
22. The pharmaceutical composition of claim 14 or 15 wherein the composition further comprises a fat-soluble antioxidant selected from the group consisting of ascorbyl palmitate, tocopherols, and ascorbic acid in the presence of lecithin.
23. The pharmaceutical composition of claim 14 or 15 wherein the composition further comprises an additive selected from the group consisting of aggregants, disaggregants, osmotic pressure regulating salts, buffers, sweeteners, and coloring agents.
24. A pharmaceutical composition of 13-HODE comprising 13-HODE and omega-3 fatty acids.
25. The pharmaceutical composition of claim 24, wherein the omega-3 fatty acid is selected from the group consisting of EPA, DHA, a derivative of EPA
and a derivative of DHA.
and a derivative of DHA.
26. The pharmaceutical composition of claim 24, wherein the omega-3 fatty acid is selected from the group consisting of ethyl-EPA and ethyl-DHA.
27. The use of the pharmaceutical composition of claim 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 to treat:
(a) cardiovascular or cerebrovascular disease (b) inflammatory or autoimmune disease (c) infection with bacteria, viruses, fungi, or protozoa, (d) respiratory disease (e) gastrointestinal disease (f) renal or urinary tract disease (g) skin disease (h) neurological or psychiatric disease (i) disease of the reproductive system (j) diabetes, syndrome A or any complication of diabetes
(a) cardiovascular or cerebrovascular disease (b) inflammatory or autoimmune disease (c) infection with bacteria, viruses, fungi, or protozoa, (d) respiratory disease (e) gastrointestinal disease (f) renal or urinary tract disease (g) skin disease (h) neurological or psychiatric disease (i) disease of the reproductive system (j) diabetes, syndrome A or any complication of diabetes
28. The use of the pharmaceutical composition of claim 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 to treat a disease or condition associated with overactive protein kinases.
29. The use of claim 28 wherein the disease or condition is associated with increase in Protein Kinase C activity and/ or an increase in Mitogen Activated Protein Kinase activity.
30. The use of the pharmaceutical composition of claim 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 to treat a disease or condition where endothelial function is disordered.
31. The use of the pharmaceutical composition of claim 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23 to treat cancer or the metastatic spread of cancer.
32. The use of the pharmaceutical composition of claim 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23 to prevent cancer or the metastatic spread of cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2403566A CA2403566C (en) | 2000-04-07 | 2001-04-06 | Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2,304,906 | 2000-04-07 | ||
| CA002304906A CA2304906A1 (en) | 2000-04-07 | 2000-04-07 | 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia |
| PCT/CA2001/000477 WO2001076568A2 (en) | 2000-04-07 | 2001-04-06 | Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia |
| CA2403566A CA2403566C (en) | 2000-04-07 | 2001-04-06 | Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2403566A1 true CA2403566A1 (en) | 2001-10-18 |
| CA2403566C CA2403566C (en) | 2010-02-23 |
Family
ID=25681713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2403566A Expired - Fee Related CA2403566C (en) | 2000-04-07 | 2001-04-06 | Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2403566C (en) |
-
2001
- 2001-04-06 CA CA2403566A patent/CA2403566C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2403566C (en) | 2010-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2001076568B1 (en) | Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia | |
| KR100657642B1 (en) | Oil comprising eicosapentaenoic acid and/or stearidonic acid | |
| EP0347056B1 (en) | Essential fatty acid compositions | |
| CA2411368C (en) | Therapeutic combinations of fatty acids | |
| JP3008213B2 (en) | Pharmaceutical composition | |
| EP1275399B1 (en) | Method and preparation for preventing and/or treating vascular disorders and secondary disorders associated therewith | |
| JP2722227B2 (en) | Fatty acid composition | |
| EP1237545B1 (en) | Use of stearidonic acid in the manufacture of a medicament for the treatment or prevention of cancer | |
| KR20010102183A (en) | Essential fatty acids in the prevention of cardiovascular events | |
| JPH02104522A (en) | Fatty acid composition | |
| AU762246B2 (en) | Method and composition for treatment of inflammatory conditions | |
| US20020002154A1 (en) | Method and composition for treatment of inflammatory conditions | |
| CA2073913A1 (en) | Preparation of fatty acid medicaments | |
| CA1287297C (en) | Iron - containing compositions and method for treatment of cancer | |
| US20160051506A1 (en) | Fat Emulsion for Artificially Feeding Seriously Ill Intensive Care Patients | |
| IE54558B1 (en) | Pharmaceutical composition | |
| US5516801A (en) | Fatty acid treatment for ectopic calcium deposition | |
| JPH0717515B2 (en) | Composition for treating benign prostatic hypertrophy | |
| AU666748B2 (en) | Fatty acid treatment | |
| US20100239660A1 (en) | Product and use of omega-3s matching human tissue ratios for treatment of inflammatory and other conditions | |
| CA2403566A1 (en) | Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia | |
| CA1197782A (en) | Pharmaceutical and dietary composition | |
| JP2020503388A (en) | Omega-3 fatty acid composition for preventing and / or treating cachexia | |
| WO2005046668A1 (en) | Preventive/therapeutic agent for speech disorder | |
| CA2504280A1 (en) | Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20160406 |